ID   MK01_HUMAN              Reviewed;         360 AA.
AC   P28482; A8CZ64;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   12-OCT-2022, entry version 243.
DE   RecName: Full=Mitogen-activated protein kinase 1 {ECO:0000305};
DE            Short=MAP kinase 1;
DE            Short=MAPK 1;
DE            EC=2.7.11.24;
DE   AltName: Full=ERT1;
DE   AltName: Full=Extracellular signal-regulated kinase 2;
DE            Short=ERK-2;
DE   AltName: Full=MAP kinase isoform p42;
DE            Short=p42-MAPK;
DE   AltName: Full=Mitogen-activated protein kinase 2;
DE            Short=MAP kinase 2;
DE            Short=MAPK 2;
GN   Name=MAPK1 {ECO:0000312|HGNC:HGNC:6871}; Synonyms=ERK2, PRKM1, PRKM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1540184; DOI=10.1016/0006-291x(92)91891-s;
RA   Owaki H., Makar R., Boulton T.G., Cobb M.H., Geppert T.D.;
RT   "Extracellular signal-regulated kinases in T cells: characterization of
RT   human ERK1 and ERK2 cDNAs.";
RL   Biochem. Biophys. Res. Commun. 182:1416-1422(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1319925; DOI=10.1016/0014-5793(92)80612-k;
RA   Gonzalez F.A., Raden D.L., Rigby M.R., Davis R.J.;
RT   "Heterogeneous expression of four MAP kinase isoforms in human tissues.";
RL   FEBS Lett. 304:170-178(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RA   Cheng H., Ren S., Qiu R., Wang M., Feng Y.H.;
RT   "Identification of dominant negative Erk1/2 variants in cancer cells.";
RL   Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-15, AND ACETYLATION AT ALA-2.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF ERF.
RX   PubMed=7588608; DOI=10.1002/j.1460-2075.1995.tb00160.x;
RA   Sgouras D.N., Athanasiou M.A., Beal G.J. Jr., Fisher R.J., Blair D.G.,
RA   Mavrothalassitis G.J.;
RT   "ERF: an ETS domain protein with strong transcriptional repressor activity,
RT   can suppress ets-associated tumorigenesis and is regulated by
RT   phosphorylation during cell cycle and mitogenic stimulation.";
RL   EMBO J. 14:4781-4793(1995).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF MAPKAPK3.
RX   PubMed=8622688; DOI=10.1128/mcb.16.3.868;
RA   Sithanandam G., Latif F., Duh F.-M., Bernal R., Smola U., Li H., Kuzmin I.,
RA   Wixler V., Geil L., Shrestha S., Lloyd P.A., Bader S., Sekido Y.,
RA   Tartof K.D., Kashuba V.I., Zabarovsky E.R., Dean M., Klein G., Lerman M.I.,
RA   Minna J.D., Rapp U.R., Allikmets R.;
RT   "3pK, a new mitogen-activated protein kinase-activated protein kinase
RT   located in the small cell lung cancer tumor suppressor gene region.";
RL   Mol. Cell. Biol. 16:868-876(1996).
RN   [9]
RP   INTERACTION WITH HIV-1 NEF (MICROBIAL INFECTION).
RX   PubMed=8794306; DOI=10.1128/jvi.70.10.6701-6708.1996;
RA   Greenway A.L., Azad A., Mills J., McPhee D.A.;
RT   "Human immunodeficiency virus type 1 Nef binds directly to LCK and mitogen-
RT   activated protein kinase, inhibiting kinase activity.";
RL   J. Virol. 70:6701-6708(1996).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF MAPKAPK5.
RX   PubMed=9480836; DOI=10.1006/bbrc.1998.8135;
RA   Ni H., Wang X.S., Diener K., Yao Z.;
RT   "MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated
RT   protein kinase, is a substrate of the extracellular-regulated kinase (ERK)
RT   and p38 kinase.";
RL   Biochem. Biophys. Res. Commun. 243:492-496(1998).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF RPS6KA5/MSK1.
RX   PubMed=9687510; DOI=10.1093/emboj/17.15.4426;
RA   Deak M., Clifton A.D., Lucocq J.M., Alessi D.R.;
RT   "Mitogen- and stress-activated protein kinase-1 (MSK1) is directly
RT   activated by MAPK and SAPK2/p38, and may mediate activation of CREB.";
RL   EMBO J. 17:4426-4441(1998).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF BCL6.
RX   PubMed=9649500; DOI=10.1101/gad.12.13.1953;
RA   Niu H., Ye B.H., Dalla-Favera R.;
RT   "Antigen receptor signaling induces MAP kinase-mediated phosphorylation and
RT   degradation of the BCL-6 transcription factor.";
RL   Genes Dev. 12:1953-1961(1998).
RN   [13]
RP   INTERACTION WITH DUSP7.
RX   PubMed=9788880; DOI=10.1242/jcs.111.22.3389;
RA   Dowd S., Sneddon A.A., Keyse S.M.;
RT   "Isolation of the human genes encoding the Pyst1 and Pyst2 phosphatases:
RT   characterisation of Pyst2 as a cytosolic dual-specificity MAP kinase
RT   phosphatase and its catalytic activation by both MAP and SAP kinases.";
RL   J. Cell Sci. 111:3389-3399(1998).
RN   [14]
RP   INTERACTION WITH DUSP6, AND FUNCTION.
RX   PubMed=9596579; DOI=10.1126/science.280.5367.1262;
RA   Camps M., Nichols A., Gillieron C., Antonsson B., Muda M., Chabert C.,
RA   Boschert U., Arkinstall S.;
RT   "Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated
RT   protein kinase.";
RL   Science 280:1262-1265(1998).
RN   [15]
RP   DEPHOSPHORYLATION BY DUSP3.
RX   PubMed=10224087; DOI=10.1074/jbc.274.19.13271;
RA   Todd J.L., Tanner K.G., Denu J.M.;
RT   "Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates
RT   for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in
RT   down-regulating the ERK pathway.";
RL   J. Biol. Chem. 274:13271-13280(1999).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF ELK1.
RX   PubMed=10637505; DOI=10.1038/sj.onc.1203362;
RA   Cruzalegui F.H., Cano E., Treisman R.;
RT   "ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs
RT   to high stoichiometry.";
RL   Oncogene 18:7948-7957(1999).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF DUSP1.
RX   PubMed=10617468; DOI=10.1126/science.286.5449.2514;
RA   Brondello J.M., Pouyssegur J., McKenzie F.R.;
RT   "Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent
RT   phosphorylation.";
RL   Science 286:2514-2517(1999).
RN   [18]
RP   FUNCTION AS MKNK2 KINASE.
RX   PubMed=11154262; DOI=10.1128/mcb.21.3.743-754.2001;
RA   Scheper G.C., Morrice N.A., Kleijn M., Proud C.G.;
RT   "The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a
RT   eukaryotic initiation factor 4E kinase with high levels of basal activity
RT   in mammalian cells.";
RL   Mol. Cell. Biol. 21:743-754(2001).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF ATF2.
RX   PubMed=12110590; DOI=10.1093/emboj/cdf361;
RA   Ouwens D.M., de Ruiter N.D., van der Zon G.C., Carter A.P., Schouten J.,
RA   van der Burgt C., Kooistra K., Bos J.L., Maassen J.A., van Dam H.;
RT   "Growth factors can activate ATF2 via a two-step mechanism: phosphorylation
RT   of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-
RT   p38.";
RL   EMBO J. 21:3782-3793(2002).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF IER3, INTERACTION WITH IER3, AND ACTIVITY
RP   REGULATION.
RX   PubMed=12356731; DOI=10.1093/emboj/cdf488;
RA   Garcia J., Ye Y., Arranz V., Letourneux C., Pezeron G., Porteu F.;
RT   "IEX-1: a new ERK substrate involved in both ERK survival activity and ERK
RT   activation.";
RL   EMBO J. 21:5151-5163(2002).
RN   [21]
RP   INTERACTION WITH NISCH.
RX   PubMed=11912194; DOI=10.1074/jbc.m111838200;
RA   Sano H., Liu S.C.H., Lane W.S., Piletz J.E., Lienhard G.E.;
RT   "Insulin receptor substrate 4 associates with the protein IRAS.";
RL   J. Biol. Chem. 277:19439-19447(2002).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF FRS2.
RX   PubMed=12974390; DOI=10.1515/bc.2003.134;
RA   Wu Y., Chen Z., Ullrich A.;
RT   "EGFR and FGFR signaling through FRS2 is subject to negative feedback
RT   control by ERK1/2.";
RL   Biol. Chem. 384:1215-1226(2003).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF DUSP16.
RX   PubMed=12794087; DOI=10.1074/jbc.m213254200;
RA   Masuda K., Shima H., Katagiri C., Kikuchi K.;
RT   "Activation of ERK induces phosphorylation of MAPK phosphatase-7, a JNK
RT   specific phosphatase, at Ser-446.";
RL   J. Biol. Chem. 278:32448-32456(2003).
RN   [24]
RP   FUNCTION IN PHOSPHORYLATION OF CASP9.
RX   PubMed=12792650; DOI=10.1038/ncb1005;
RA   Allan L.A., Morrice N., Brady S., Magee G., Pathak S., Clarke P.R.;
RT   "Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK.";
RL   Nat. Cell Biol. 5:647-654(2003).
RN   [25]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH NEK2.
RX   PubMed=15358203; DOI=10.1016/j.bbrc.2004.06.171;
RA   Lou Y., Xie W., Zhang D.F., Yao J.H., Luo Z.F., Wang Y.Z., Shi Y.Y.,
RA   Yao X.B.;
RT   "Nek2A specifies the centrosomal localization of Erk2.";
RL   Biochem. Biophys. Res. Commun. 321:495-501(2004).
RN   [26]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF SORBS3.
RX   PubMed=15184391; DOI=10.1074/jbc.m402304200;
RA   Mitsushima M., Suwa A., Amachi T., Ueda K., Kioka N.;
RT   "Extracellular signal-regulated kinase activated by epidermal growth factor
RT   and cell adhesion interacts with and phosphorylates vinexin.";
RL   J. Biol. Chem. 279:34570-34577(2004).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF MCL1.
RX   PubMed=15241487; DOI=10.1038/sj.onc.1207692;
RA   Domina A.M., Vrana J.A., Gregory M.A., Hann S.R., Craig R.W.;
RT   "MCL1 is phosphorylated in the PEST region and stabilized upon ERK
RT   activation in viable cells, and at additional sites with cytotoxic okadaic
RT   acid or taxol.";
RL   Oncogene 23:5301-5315(2004).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF GRB10.
RX   PubMed=15952796; DOI=10.1021/bi050413i;
RA   Langlais P., Wang C., Dong L.Q., Carroll C.A., Weintraub S.T., Liu F.;
RT   "Phosphorylation of Grb10 by mitogen-activated protein kinase:
RT   identification of Ser150 and Ser476 of human Grb10zeta as major
RT   phosphorylation sites.";
RL   Biochemistry 44:8890-8897(2005).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF DAPK1, SUBCELLULAR LOCATION, AND INTERACTION
RP   WITH DAPK1.
RX   PubMed=15616583; DOI=10.1038/sj.emboj.7600510;
RA   Chen C.H., Wang W.J., Kuo J.C., Tsai H.C., Lin J.R., Chang Z.F., Chen R.H.;
RT   "Bidirectional signals transduced by DAPK-ERK interaction promote the
RT   apoptotic effect of DAPK.";
RL   EMBO J. 24:294-304(2005).
RN   [31]
RP   DEPHOSPHORYLATION AT THR-185 AND TYR-187 BY DUSP2.
RX   PubMed=16288922; DOI=10.1016/j.jmb.2005.10.006;
RA   Zhang Q., Muller M., Chen C.H., Zeng L., Farooq A., Zhou M.M.;
RT   "New insights into the catalytic activation of the MAPK phosphatase PAC-1
RT   induced by its substrate MAPK ERK2 binding.";
RL   J. Mol. Biol. 354:777-788(2005).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF BTG2.
RX   PubMed=15788397; DOI=10.1074/jbc.m500318200;
RA   Hong J.W., Ryu M.S., Lim I.K.;
RT   "Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces Pin-1
RT   binding in cytoplasm and cell death.";
RL   J. Biol. Chem. 280:21256-21263(2005).
RN   [33]
RP   FUNCTION IN PHOSPHORYLATION OF RAF1.
RX   PubMed=15664191; DOI=10.1016/j.molcel.2004.11.055;
RA   Dougherty M.K., Muller J., Ritt D.A., Zhou M., Zhou X.Z., Copeland T.D.,
RA   Conrads T.P., Veenstra T.D., Lu K.P., Morrison D.K.;
RT   "Regulation of Raf-1 by direct feedback phosphorylation.";
RL   Mol. Cell 17:215-224(2005).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [35]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=18211802; DOI=10.1016/j.bbrc.2008.01.066;
RA   Fujishiro S.H., Tanimura S., Mure S., Kashimoto Y., Watanabe K., Kohno M.;
RT   "ERK1/2 phosphorylate GEF-H1 to enhance its guanine nucleotide exchange
RT   activity toward RhoA.";
RL   Biochem. Biophys. Res. Commun. 368:162-167(2008).
RN   [36]
RP   FUNCTION, AND INTERACTION WITH HSF4.
RX   PubMed=16581800; DOI=10.1128/mcb.26.8.3282-3294.2006;
RA   Hu Y., Mivechi N.F.;
RT   "Association and regulation of heat shock transcription factor 4b with both
RT   extracellular signal-regulated kinase mitogen-activated protein kinase and
RT   dual-specificity tyrosine phosphatase DUSP26.";
RL   Mol. Cell. Biol. 26:3282-3294(2006).
RN   [37]
RP   PHOSPHORYLATION.
RX   PubMed=17274988; DOI=10.1016/j.febslet.2007.01.039;
RA   Degoutin J., Vigny M., Gouzi J.Y.;
RT   "ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic
RT   outcomes in PC12 cells differentiation.";
RL   FEBS Lett. 581:727-734(2007).
RN   [38]
RP   INTERACTION WITH ARRB2.
RX   PubMed=18435604; DOI=10.1042/bj20080685;
RA   Xu T.-R., Baillie G.S., Bhari N., Houslay T.M., Pitt A.M., Adams D.R.,
RA   Kolch W., Houslay M.D., Milligan G.;
RT   "Mutations of beta-arrestin 2 that limit self-association also interfere
RT   with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs:
RT   implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs.";
RL   Biochem. J. 413:51-60(2008).
RN   [39]
RP   INTERACTION WITH ADAM15.
RX   PubMed=18296648; DOI=10.1158/1541-7786.mcr-07-2028;
RA   Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M.,
RA   Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C.,
RA   Edwards D.R.;
RT   "Distinct functions of natural ADAM-15 cytoplasmic domain variants in human
RT   mammary carcinoma.";
RL   Mol. Cancer Res. 6:383-394(2008).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [41]
RP   PHOSPHORYLATION AT SER-246 AND SER-248, INTERACTION WITH IPO7, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=18760948; DOI=10.1016/j.molcel.2008.08.007;
RA   Chuderland D., Konson A., Seger R.;
RT   "Identification and characterization of a general nuclear translocation
RT   signal in signaling proteins.";
RL   Mol. Cell 31:850-861(2008).
RN   [42]
RP   FUNCTION IN PHOSPHORYLATION OF TPR, INTERACTION WITH TPR, AND MUTAGENESIS
RP   OF LYS-54; 176-PRO--ASP-179; THR-185; TYR-187; LEU-234; ASP-318 AND
RP   ASP-321.
RX   PubMed=18794356; DOI=10.1128/mcb.00925-08;
RA   Vomastek T., Iwanicki M.P., Burack W.R., Tiwari D., Kumar D., Parsons J.T.,
RA   Weber M.J., Nandicoori V.K.;
RT   "Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and
RT   docking domain on the nuclear pore complex protein Tpr cooperatively
RT   regulate ERK2-Tpr interaction.";
RL   Mol. Cell. Biol. 28:6954-6966(2008).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-185 AND TYR-187, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [44]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [45]
RP   FUNCTION AS A TRANSCRIPTIONAL REPRESSOR, AND DNA-BINDING.
RX   PubMed=19879846; DOI=10.1016/j.cell.2009.08.037;
RA   Hu S., Xie Z., Onishi A., Yu X., Jiang L., Lin J., Rho H.-S., Woodard C.,
RA   Wang H., Jeong J.-S., Long S., He X., Wade H., Blackshaw S., Qian J.,
RA   Zhu H.;
RT   "Profiling the human protein-DNA interactome reveals ERK2 as a
RT   transcriptional repressor of interferon signaling.";
RL   Cell 139:610-622(2009).
RN   [46]
RP   FUNCTION IN KIT SIGNALING PATHWAY, AND PHOSPHORYLATION.
RX   PubMed=19265199; DOI=10.1074/jbc.m808058200;
RA   Sun J., Pedersen M., Ronnstrand L.;
RT   "The D816V mutation of c-Kit circumvents a requirement for Src family
RT   kinases in c-Kit signal transduction.";
RL   J. Biol. Chem. 284:11039-11047(2009).
RN   [47]
RP   PHOSPHORYLATION AT TYR-187, DEPHOSPHORYLATION AT TYR-187 BY PTPRJ, AND
RP   MUTAGENESIS OF ASP-318.
RX   PubMed=19494114; DOI=10.1074/jbc.m109.002758;
RA   Sacco F., Tinti M., Palma A., Ferrari E., Nardozza A.P.,
RA   Hooft van Huijsduijnen R., Takahashi T., Castagnoli L., Cesareni G.;
RT   "Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS
RT   pathway by direct dephosphorylation of ERK1/2 kinases.";
RL   J. Biol. Chem. 284:22048-22058(2009).
RN   [48]
RP   PHOSPHORYLATION AT SER-29 BY SGK1, AND INTERACTION WITH SGK1.
RX   PubMed=19447520; DOI=10.1016/j.jhep.2009.02.027;
RA   Won M., Park K.A., Byun H.S., Kim Y.R., Choi B.L., Hong J.H., Park J.,
RA   Seok J.H., Lee Y.H., Cho C.H., Song I.S., Kim Y.K., Shen H.M., Hur G.M.;
RT   "Protein kinase SGK1 enhances MEK/ERK complex formation through the
RT   phosphorylation of ERK2: implication for the positive regulatory role of
RT   SGK1 on the ERK function during liver regeneration.";
RL   J. Hepatol. 51:67-76(2009).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-284, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [50]
RP   PHOSPHORYLATION AT THR-190, ACTIVITY REGULATION, SUBUNIT, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19060905; DOI=10.1038/nm.1893;
RA   Lorenz K., Schmitt J.P., Schmitteckert E.M., Lohse M.J.;
RT   "A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy.";
RL   Nat. Med. 15:75-83(2009).
RN   [51]
RP   REVIEW ON FUNCTION.
RX   PubMed=16393692; DOI=10.1080/02699050500284218;
RA   Yoon S., Seger R.;
RT   "The extracellular signal-regulated kinase: multiple substrates regulate
RT   diverse cellular functions.";
RL   Growth Factors 24:21-44(2006).
RN   [52]
RP   REVIEW ON FUNCTION, AND REVIEW ON SUBCELLULAR LOCATION.
RX   PubMed=19565474; DOI=10.1002/biof.52;
RA   Yao Z., Seger R.;
RT   "The ERK signaling cascade--views from different subcellular
RT   compartments.";
RL   BioFactors 35:407-416(2009).
RN   [53]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-185 AND TYR-187, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [54]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [55]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [56]
RP   REVIEW ON ACTIVITY REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=21779493; DOI=10.1177/1947601911407328;
RA   Wortzel I., Seger R.;
RT   "The ERK cascade: distinct functions within various subcellular
RT   organelles.";
RL   Genes Cancer 2:195-209(2011).
RN   [57]
RP   FUNCTION, AND INTERACTION WITH PML.
RX   PubMed=22033920; DOI=10.1074/jbc.m111.289512;
RA   Lim J.H., Liu Y., Reineke E., Kao H.Y.;
RT   "Mitogen-activated protein kinase extracellular signal-regulated kinase 2
RT   phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia
RT   protein turnover.";
RL   J. Biol. Chem. 286:44403-44411(2011).
RN   [58]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-185 AND TYR-187, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [59]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [60]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [61]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-185 AND TYR-187, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [62]
RP   INTERACTION WITH STYX.
RX   PubMed=23847209; DOI=10.1073/pnas.1301985110;
RA   Reiterer V., Fey D., Kolch W., Kholodenko B.N., Farhan H.;
RT   "Pseudophosphatase STYX modulates cell-fate decisions and cell migration by
RT   spatiotemporal regulation of ERK1/2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:E2934-2943(2013).
RN   [63]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [64]
RP   INTERACTION WITH ZNF263.
RX   PubMed=32051553; DOI=10.1038/s41388-020-1206-7;
RA   Yu Z., Feng J., Wang W., Deng Z., Zhang Y., Xiao L., Wang Z., Liu C.,
RA   Liu Q., Chen S., Wu M.;
RT   "The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma
RT   epigenetically.";
RL   Oncogene 39:3163-3178(2020).
RN   [65] {ECO:0007744|PDB:1PME}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=9827991; DOI=10.1002/pro.5560071102;
RA   Fox T., Coll J.T., Xie X., Ford P.J., Germann U.A., Porter M.D.,
RA   Pazhanisamy S., Fleming M.A., Galullo V., Su M.S., Wilson K.P.;
RT   "A single amino acid substitution makes ERK2 susceptible to pyridinyl
RT   imidazole inhibitors of p38 MAP kinase.";
RL   Protein Sci. 7:2249-2255(1998).
RN   [66] {ECO:0007744|PDB:1TVO}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=16139248; DOI=10.1016/j.bbrc.2005.08.082;
RA   Ohori M., Kinoshita T., Okubo M., Sato K., Yamazaki A., Arakawa H.,
RA   Nishimura S., Inamura N., Nakajima H., Neya M., Miyake H., Fujii T.;
RT   "Identification of a selective ERK inhibitor and structural determination
RT   of the inhibitor-ERK2 complex.";
RL   Biochem. Biophys. Res. Commun. 336:357-363(2005).
RN   [67] {ECO:0007744|PDB:1WZY}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=16242327; DOI=10.1016/j.bmcl.2005.09.055;
RA   Kinoshita T., Warizaya M., Ohori M., Sato K., Neya M., Fujii T.;
RT   "Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine
RT   derivative.";
RL   Bioorg. Med. Chem. Lett. 16:55-58(2006).
RN   [68] {ECO:0007744|PDB:3W55}
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=17194451; DOI=10.1016/j.bbrc.2006.12.083;
RA   Ohori M., Kinoshita T., Yoshimura S., Warizaya M., Nakajima H., Miyake H.;
RT   "Role of a cysteine residue in the active site of ERK and the MAPKK
RT   family.";
RL   Biochem. Biophys. Res. Commun. 353:633-637(2007).
RN   [69] {ECO:0007744|PDB:2OJG, ECO:0007744|PDB:2OJI, ECO:0007744|PDB:2OJJ}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-359 IN COMPLEX WITH INHIBITOR.
RX   PubMed=17300186; DOI=10.1021/jm061381f;
RA   Aronov A.M., Baker C., Bemis G.W., Cao J., Chen G., Ford P.J.,
RA   Germann U.A., Green J., Hale M.R., Jacobs M., Janetka J.W., Maltais F.,
RA   Martinez-Botella G., Namchuk M.N., Straub J., Tang Q., Xie X.;
RT   "Flipped out: structure-guided design of selective pyrazolylpyrrole ERK
RT   inhibitors.";
RL   J. Med. Chem. 50:1280-1287(2007).
RN   [70] {ECO:0007744|PDB:3D42, ECO:0007744|PDB:3D44}
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 186-191, AND PHOSPHORYLATION AT
RP   TYR-187.
RX   PubMed=19053285; DOI=10.1021/bi801724n;
RA   Critton D.A., Tortajada A., Stetson G., Peti W., Page R.;
RT   "Structural basis of substrate recognition by hematopoietic tyrosine
RT   phosphatase.";
RL   Biochemistry 47:13336-13345(2008).
RN   [71] {ECO:0007744|PDB:3I5Z, ECO:0007744|PDB:3I60}
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=19827834; DOI=10.1021/jm900630q;
RA   Aronov A.M., Tang Q., Martinez-Botella G., Bemis G.W., Cao J., Chen G.,
RA   Ewing N.P., Ford P.J., Germann U.A., Green J., Hale M.R., Jacobs M.,
RA   Janetka J.W., Maltais F., Markland W., Namchuk M.N., Nanthakumar S.,
RA   Poondru S., Straub J., ter Haar E., Xie X.;
RT   "Structure-guided design of potent and selective pyrimidylpyrrole
RT   inhibitors of extracellular signal-regulated kinase (ERK) using
RT   conformational control.";
RL   J. Med. Chem. 52:6362-6368(2009).
RN   [72]
RP   VARIANTS NS13 ASN-74; TYR-80; VAL-174; ASN-318; GLY-318; GLN-322 AND
RP   ARG-323, INVOLVEMENT IN NS13, CHARACTERIZATION OF VARIANTS NS13 ASN-74;
RP   TYR-80; VAL-174; ASN-318; GLY-318 AND ARG-323, SUBCELLULAR LOCATION,
RP   FUNCTION, AND INTERACTION WITH MAP2K1 AND DUSP6.
RX   PubMed=32721402; DOI=10.1016/j.ajhg.2020.06.018;
RA   Motta M., Pannone L., Pantaleoni F., Bocchinfuso G., Radio F.C.,
RA   Cecchetti S., Ciolfi A., Di Rocco M., Elting M.W., Brilstra E.H., Boni S.,
RA   Mazzanti L., Tamburrino F., Walsh L., Payne K., Fernandez-Jaen A.,
RA   Ganapathi M., Chung W.K., Grange D.K., Dave-Wala A., Reshmi S.C.,
RA   Bartholomew D.W., Mouhlas D., Carpentieri G., Bruselles A., Pizzi S.,
RA   Bellacchio E., Piceci-Sparascio F., Lissewski C., Brinkmann J.,
RA   Waclaw R.R., Waisfisz Q., van Gassen K., Wentzensen I.M., Morrow M.M.,
RA   Alvarez S., Martinez-Garcia M., De Luca A., Memo L., Zampino G., Rossi C.,
RA   Seri M., Gelb B.D., Zenker M., Dallapiccola B., Stella L., Prada C.E.,
RA   Martinelli S., Flex E., Tartaglia M.;
RT   "Enhanced MAPK1 function causes a neurodevelopmental disorder within the
RT   RASopathy clinical spectrum.";
RL   Am. J. Hum. Genet. 107:499-513(2020).
CC   -!- FUNCTION: Serine/threonine kinase which acts as an essential component
CC       of the MAP kinase signal transduction pathway. MAPK1/ERK2 and
CC       MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK
CC       cascade. They participate also in a signaling cascade initiated by
CC       activated KIT and KITLG/SCF. Depending on the cellular context, the
CC       MAPK/ERK cascade mediates diverse biological functions such as cell
CC       growth, adhesion, survival and differentiation through the regulation
CC       of transcription, translation, cytoskeletal rearrangements. The
CC       MAPK/ERK cascade also plays a role in initiation and regulation of
CC       meiosis, mitosis, and postmitotic functions in differentiated cells by
CC       phosphorylating a number of transcription factors. About 160 substrates
CC       have already been discovered for ERKs. Many of these substrates are
CC       localized in the nucleus, and seem to participate in the regulation of
CC       transcription upon stimulation. However, other substrates are found in
CC       the cytosol as well as in other cellular organelles, and those are
CC       responsible for processes such as translation, mitosis and apoptosis.
CC       Moreover, the MAPK/ERK cascade is also involved in the regulation of
CC       the endosomal dynamics, including lysosome processing and endosome
CC       cycling through the perinuclear recycling compartment (PNRC); as well
CC       as in the fragmentation of the Golgi apparatus during mitosis. The
CC       substrates include transcription factors (such as ATF2, BCL6, ELK1,
CC       ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN,
CC       GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such
CC       as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of
CC       translation (such as EIF4EBP1) and a variety of other signaling-related
CC       molecules (like ARHGEF2, DCC, FRS2 or GRB10). Protein kinases (such as
CC       RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK,
CC       MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or
CC       MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are
CC       other substrates which enable the propagation the MAPK/ERK signal to
CC       additional cytosolic and nuclear targets, thereby extending the
CC       specificity of the cascade. Mediates phosphorylation of TPR in response
CC       to EGF stimulation. May play a role in the spindle assembly checkpoint.
CC       Phosphorylates PML and promotes its interaction with PIN1, leading to
CC       PML degradation. Phosphorylates CDK2AP2 (By similarity).
CC       {ECO:0000250|UniProtKB:P63086, ECO:0000269|PubMed:10617468,
CC       ECO:0000269|PubMed:10637505, ECO:0000269|PubMed:11154262,
CC       ECO:0000269|PubMed:12110590, ECO:0000269|PubMed:12356731,
CC       ECO:0000269|PubMed:12792650, ECO:0000269|PubMed:12794087,
CC       ECO:0000269|PubMed:12974390, ECO:0000269|PubMed:15184391,
CC       ECO:0000269|PubMed:15241487, ECO:0000269|PubMed:15616583,
CC       ECO:0000269|PubMed:15664191, ECO:0000269|PubMed:15788397,
CC       ECO:0000269|PubMed:15952796, ECO:0000269|PubMed:16581800,
CC       ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19265199,
CC       ECO:0000269|PubMed:19879846, ECO:0000269|PubMed:22033920,
CC       ECO:0000269|PubMed:32721402, ECO:0000269|PubMed:7588608,
CC       ECO:0000269|PubMed:8622688, ECO:0000269|PubMed:9480836,
CC       ECO:0000269|PubMed:9596579, ECO:0000269|PubMed:9649500,
CC       ECO:0000269|PubMed:9687510, ECO:0000303|PubMed:15526160,
CC       ECO:0000303|PubMed:16393692, ECO:0000303|PubMed:19565474,
CC       ECO:0000303|PubMed:21779493}.
CC   -!- FUNCTION: Acts as a transcriptional repressor. Binds to a [GC]AAA[GC]
CC       consensus sequence. Repress the expression of interferon gamma-induced
CC       genes. Seems to bind to the promoter of CCL5, DMP1, IFIH1, IFITM1,
CC       IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 and STAT1. Transcriptional activity
CC       is independent of kinase activity. {ECO:0000269|PubMed:19879846}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.24;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Phosphorylated by MAP2K1/MEK1 and MAP2K2/MEK2 on
CC       Thr-185 and Tyr-187 in response to external stimuli like insulin or
CC       NGF. Both phosphorylations are required for activity. This
CC       phosphorylation causes dramatic conformational changes, which enable
CC       full activation and interaction of MAPK1/ERK2 with its substrates.
CC       Phosphorylation on Ser-29 by SGK1 results in its activation by
CC       enhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2.
CC       Dephosphorylated and inactivated by DUSP1, DUSP3, DUSP6 and DUSP9.
CC       Inactivated by pyrimidylpyrrole inhibitors.
CC       {ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:19060905}.
CC   -!- SUBUNIT: Binds both upstream activators and downstream substrates in
CC       multimolecular complexes. This interaction inhibits its tyrosine-kinase
CC       activity. Interacts with ADAM15, ARHGEF2, ARRB2, DAPK1 (via death
CC       domain), HSF4, IER3, IPO7, NISCH, SGK1, and isoform 1 of NEK2.
CC       Interacts (via phosphorylated form) with TPR (via C-terminal region and
CC       phosphorylated form); the interaction requires dimerization of
CC       MAPK1/ERK2 and increases following EGF stimulation (PubMed:18794356).
CC       Interacts with MAP2K1 (PubMed:32721402). Interacts with DUSP6
CC       (PubMed:9596579, PubMed:32721402). Interacts (phosphorylated form) with
CC       CAV2 ('Tyr-19'-phosphorylated form); the interaction, promoted by
CC       insulin, leads to nuclear location and MAPK1 activation. Interacts with
CC       MORG1, PEA15 and MKNK2 (By similarity). MKNK2 isoform 1 binding
CC       prevents from dephosphorylation and inactivation (By similarity).
CC       Interacts with DCC (By similarity). The phosphorylated form interacts
CC       with PML (isoform PML-4). Interacts with STYX. Interacts with CDK2AP2.
CC       Interacts with CAVIN4 (By similarity). Interacts with DUSP7; the
CC       interaction enhances DUSP7 phosphatase activity (PubMed:9788880).
CC       Interacts with GIT1; this interaction is necessary for MAPK1
CC       localization to focal adhesions (By similarity). Interacts with ZNF263
CC       (PubMed:32051553). {ECO:0000250|UniProtKB:P63085,
CC       ECO:0000250|UniProtKB:P63086, ECO:0000269|PubMed:11912194,
CC       ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:15358203,
CC       ECO:0000269|PubMed:15616583, ECO:0000269|PubMed:16139248,
CC       ECO:0000269|PubMed:16242327, ECO:0000269|PubMed:16581800,
CC       ECO:0000269|PubMed:17194451, ECO:0000269|PubMed:17300186,
CC       ECO:0000269|PubMed:18211802, ECO:0000269|PubMed:18296648,
CC       ECO:0000269|PubMed:18435604, ECO:0000269|PubMed:18760948,
CC       ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19060905,
CC       ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:19827834,
CC       ECO:0000269|PubMed:22033920, ECO:0000269|PubMed:23847209,
CC       ECO:0000269|PubMed:32051553, ECO:0000269|PubMed:32721402,
CC       ECO:0000269|PubMed:9596579, ECO:0000269|PubMed:9788880,
CC       ECO:0000269|PubMed:9827991}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Nef through its SH3
CC       domain. {ECO:0000269|PubMed:8794306}.
CC   -!- INTERACTION:
CC       P28482; P05067: APP; NbExp=3; IntAct=EBI-959949, EBI-77613;
CC       P28482; P53004: BLVRA; NbExp=2; IntAct=EBI-959949, EBI-7410441;
CC       P28482; P15882: CHN1; NbExp=3; IntAct=EBI-959949, EBI-718947;
CC       P28482; Q7L5N1: COPS6; NbExp=2; IntAct=EBI-959949, EBI-486838;
CC       P28482; P28562: DUSP1; NbExp=3; IntAct=EBI-959949, EBI-975493;
CC       P28482; Q13115: DUSP4; NbExp=6; IntAct=EBI-959949, EBI-6591081;
CC       P28482; Q16690: DUSP5; NbExp=3; IntAct=EBI-959949, EBI-7487376;
CC       P28482; Q16828: DUSP6; NbExp=5; IntAct=EBI-959949, EBI-746870;
CC       P28482; Q99956: DUSP9; NbExp=4; IntAct=EBI-959949, EBI-3906678;
CC       P28482; Q9BRK4: LZTS2; NbExp=4; IntAct=EBI-959949, EBI-741037;
CC       P28482; Q02750: MAP2K1; NbExp=2; IntAct=EBI-959949, EBI-492564;
CC       P28482; P28482: MAPK1; NbExp=3; IntAct=EBI-959949, EBI-959949;
CC       P28482; Q16539-3: MAPK14; NbExp=5; IntAct=EBI-959949, EBI-6932370;
CC       P28482; Q99750: MDFI; NbExp=3; IntAct=EBI-959949, EBI-724076;
CC       P28482; Q9BUB5: MKNK1; NbExp=10; IntAct=EBI-959949, EBI-73837;
CC       P28482; P35548: MSX2; NbExp=3; IntAct=EBI-959949, EBI-6447480;
CC       P28482; Q15121: PEA15; NbExp=4; IntAct=EBI-959949, EBI-714410;
CC       P28482; Q9UPG8: PLAGL2; NbExp=3; IntAct=EBI-959949, EBI-2876622;
CC       P28482; P62487: POLR2G; NbExp=3; IntAct=EBI-959949, EBI-347928;
CC       P28482; P35813: PPM1A; NbExp=19; IntAct=EBI-959949, EBI-989143;
CC       P28482; Q6NYC8: PPP1R18; NbExp=3; IntAct=EBI-959949, EBI-2557469;
CC       P28482; P25786: PSMA1; NbExp=3; IntAct=EBI-959949, EBI-359352;
CC       P28482; A2A3K4: PTPDC1; NbExp=3; IntAct=EBI-959949, EBI-11603375;
CC       P28482; P35236: PTPN7; NbExp=6; IntAct=EBI-959949, EBI-2265723;
CC       P28482; Q12913: PTPRJ; NbExp=7; IntAct=EBI-959949, EBI-2264500;
CC       P28482; Q15256: PTPRR; NbExp=3; IntAct=EBI-959949, EBI-2265659;
CC       P28482; Q15256-5: PTPRR; NbExp=3; IntAct=EBI-959949, EBI-18347359;
CC       P28482; O76064: RNF8; NbExp=3; IntAct=EBI-959949, EBI-373337;
CC       P28482; Q15418: RPS6KA1; NbExp=7; IntAct=EBI-959949, EBI-963034;
CC       P28482; Q15349: RPS6KA2; NbExp=9; IntAct=EBI-959949, EBI-1384149;
CC       P28482; P51812: RPS6KA3; NbExp=7; IntAct=EBI-959949, EBI-1046616;
CC       P28482; P29353-2: SHC1; NbExp=4; IntAct=EBI-959949, EBI-1000553;
CC       P28482; P61764: STXBP1; NbExp=3; IntAct=EBI-959949, EBI-960169;
CC       P28482; Q08117-2: TLE5; NbExp=3; IntAct=EBI-959949, EBI-11741437;
CC       P28482; Q9Y296: TRAPPC4; NbExp=3; IntAct=EBI-959949, EBI-722888;
CC       P28482; B2RXF5: ZBTB42; NbExp=3; IntAct=EBI-959949, EBI-12287587;
CC       P28482; A0A384NQ31; NbExp=3; IntAct=EBI-959949, EBI-12903728;
CC       P28482; Q9U1H0: cic; Xeno; NbExp=2; IntAct=EBI-959949, EBI-98330;
CC       P28482; Q05922: Dusp2; Xeno; NbExp=2; IntAct=EBI-959949, EBI-7898692;
CC       P28482; P02687: MBP; Xeno; NbExp=2; IntAct=EBI-959949, EBI-908215;
CC       P28482; Q8VSP9: ospF; Xeno; NbExp=5; IntAct=EBI-959949, EBI-6506625;
CC       P28482; P0A2M9: spvC; Xeno; NbExp=3; IntAct=EBI-959949, EBI-15676035;
CC       P28482; Q69559: U24; Xeno; NbExp=2; IntAct=EBI-959949, EBI-8015758;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, spindle {ECO:0000250}.
CC       Nucleus {ECO:0000269|PubMed:32721402}. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome. Cytoplasm
CC       {ECO:0000269|PubMed:32721402}. Membrane, caveola
CC       {ECO:0000250|UniProtKB:P63086}. Cell junction, focal adhesion
CC       {ECO:0000250|UniProtKB:P63085}. Note=Associated with the spindle during
CC       prometaphase and metaphase (By similarity). PEA15-binding and
CC       phosphorylated DAPK1 promote its cytoplasmic retention. Phosphorylation
CC       at Ser- 246 and Ser-248 as well as autophosphorylation at Thr-190
CC       promote nuclear localization. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P28482-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P28482-2; Sequence=VSP_047815;
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Phosphorylated upon KIT and FLT3 signaling (By similarity). Dually
CC       phosphorylated on Thr-185 and Tyr-187, which activates the enzyme.
CC       Undergoes regulatory phosphorylation on additional residues such as
CC       Ser-246 and Ser-248 in the kinase insert domain (KID) These
CC       phosphorylations, which are probably mediated by more than one kinase,
CC       are important for binding of MAPK1/ERK2 to importin-7 (IPO7) and its
CC       nuclear translocation. In addition, autophosphorylation of Thr-190 was
CC       shown to affect the subcellular localization of MAPK1/ERK2 as well.
CC       Ligand-activated ALK induces tyrosine phosphorylation. Dephosphorylated
CC       by PTPRJ at Tyr-187. Phosphorylation on Ser-29 by SGK1 results in its
CC       activation by enhancing its interaction with MAP2K1/MEK1 and
CC       MAP2K2/MEK2. DUSP3 and DUSP6 dephosphorylate specifically MAPK1/ERK2
CC       and MAPK3/ERK1 whereas DUSP9 dephosphorylates a broader range of MAPKs.
CC       Dephosphorylated by DUSP1 and DUSP2 at Thr-185 and Tyr-187 (By
CC       similarity) (PubMed:16288922). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P63085, ECO:0000269|PubMed:16288922,
CC       ECO:0000269|PubMed:17274988, ECO:0000269|PubMed:18760948,
CC       ECO:0000269|PubMed:19053285, ECO:0000269|PubMed:19060905,
CC       ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:19447520,
CC       ECO:0000269|PubMed:19494114}.
CC   -!- PTM: ISGylated. {ECO:0000250}.
CC   -!- DISEASE: Noonan syndrome 13 (NS13) [MIM:619087]: A form of Noonan
CC       syndrome, a disease characterized by short stature, facial dysmorphic
CC       features such as hypertelorism, a downward eyeslant and low-set
CC       posteriorly rotated ears, and a high incidence of congenital heart
CC       defects and hypertrophic cardiomyopathy. Other features can include a
CC       short neck with webbing or redundancy of skin, deafness, motor delay,
CC       variable intellectual deficits, multiple skeletal defects,
CC       cryptorchidism, and bleeding diathesis. Individuals with Noonan
CC       syndrome are at risk of juvenile myelomonocytic leukemia, a
CC       myeloproliferative disorder characterized by excessive production of
CC       myelomonocytic cells. NS13 inheritance is autosomal dominant. There is
CC       considerable variability in severity. {ECO:0000269|PubMed:32721402}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MAP kinase subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA77753.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Extracellular signal-regulated
CC       kinase entry;
CC       URL="https://en.wikipedia.org/wiki/Extracellular_signal-regulated_kinase";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAPK1ID41288ch22q11.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M84489; AAA58459.1; -; mRNA.
DR   EMBL; Z11694; CAA77752.1; -; mRNA.
DR   EMBL; Z11695; CAA77753.1; ALT_INIT; mRNA.
DR   EMBL; DQ399292; ABD60303.1; -; mRNA.
DR   EMBL; AP000553; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000554; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000555; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC017832; AAH17832.1; -; mRNA.
DR   CCDS; CCDS13795.1; -. [P28482-1]
DR   PIR; JQ1400; JQ1400.
DR   RefSeq; NP_002736.3; NM_002745.4. [P28482-1]
DR   RefSeq; NP_620407.1; NM_138957.3. [P28482-1]
DR   PDB; 1PME; X-ray; 2.00 A; A=1-360.
DR   PDB; 1TVO; X-ray; 2.50 A; A=1-360.
DR   PDB; 1WZY; X-ray; 2.50 A; A=1-360.
DR   PDB; 2OJG; X-ray; 2.00 A; A=2-360.
DR   PDB; 2OJI; X-ray; 2.60 A; A=2-360.
DR   PDB; 2OJJ; X-ray; 2.40 A; A=2-360.
DR   PDB; 2Y9Q; X-ray; 1.55 A; A=1-360.
DR   PDB; 3D42; X-ray; 2.46 A; B=184-191.
DR   PDB; 3D44; X-ray; 1.90 A; B=184-191.
DR   PDB; 3I5Z; X-ray; 2.20 A; A=1-360.
DR   PDB; 3I60; X-ray; 2.50 A; A=1-360.
DR   PDB; 3SA0; X-ray; 1.59 A; A=1-360.
DR   PDB; 3TEI; X-ray; 2.40 A; A=1-360.
DR   PDB; 3W55; X-ray; 3.00 A; A=1-360.
DR   PDB; 4FMQ; X-ray; 2.10 A; A=1-360.
DR   PDB; 4FUX; X-ray; 2.20 A; A=1-360.
DR   PDB; 4FUY; X-ray; 2.00 A; A=1-360.
DR   PDB; 4FV0; X-ray; 2.10 A; A=1-360.
DR   PDB; 4FV1; X-ray; 1.99 A; A=1-360.
DR   PDB; 4FV2; X-ray; 2.00 A; A=1-360.
DR   PDB; 4FV3; X-ray; 2.20 A; A=1-360.
DR   PDB; 4FV4; X-ray; 2.50 A; A=1-360.
DR   PDB; 4FV5; X-ray; 2.40 A; A=1-360.
DR   PDB; 4FV6; X-ray; 2.50 A; A=1-360.
DR   PDB; 4FV7; X-ray; 1.90 A; A=1-360.
DR   PDB; 4FV8; X-ray; 2.00 A; A=1-360.
DR   PDB; 4FV9; X-ray; 2.11 A; A=1-360.
DR   PDB; 4G6N; X-ray; 2.00 A; A=1-360.
DR   PDB; 4G6O; X-ray; 2.20 A; A=1-360.
DR   PDB; 4H3P; X-ray; 2.30 A; A/D=1-360.
DR   PDB; 4H3Q; X-ray; 2.20 A; A=1-360.
DR   PDB; 4IZ5; X-ray; 3.19 A; A/B/C/D=8-360.
DR   PDB; 4IZ7; X-ray; 1.80 A; A/C=8-360.
DR   PDB; 4IZA; X-ray; 1.93 A; A/C=8-360.
DR   PDB; 4N0S; X-ray; 1.80 A; A=1-360.
DR   PDB; 4NIF; X-ray; 2.15 A; B/E=1-360.
DR   PDB; 4O6E; X-ray; 1.95 A; A=13-360.
DR   PDB; 4QP1; X-ray; 2.70 A; A/B=1-360.
DR   PDB; 4QP2; X-ray; 2.23 A; A/B=1-360.
DR   PDB; 4QP3; X-ray; 2.60 A; A/B=1-360.
DR   PDB; 4QP4; X-ray; 2.20 A; A/B=1-360.
DR   PDB; 4QP6; X-ray; 3.10 A; A/B=1-360.
DR   PDB; 4QP7; X-ray; 2.25 A; A/B=1-360.
DR   PDB; 4QP8; X-ray; 2.45 A; A/B=1-360.
DR   PDB; 4QP9; X-ray; 2.00 A; A=1-360.
DR   PDB; 4QPA; X-ray; 2.85 A; A/B=1-360.
DR   PDB; 4QTA; X-ray; 1.45 A; A=1-360.
DR   PDB; 4QTE; X-ray; 1.50 A; A=1-360.
DR   PDB; 4XJ0; X-ray; 2.58 A; A/B=12-360.
DR   PDB; 4ZXT; X-ray; 2.00 A; A=1-360.
DR   PDB; 4ZZM; X-ray; 1.89 A; A=11-360.
DR   PDB; 4ZZN; X-ray; 1.33 A; A=11-360.
DR   PDB; 4ZZO; X-ray; 1.63 A; A=11-360.
DR   PDB; 5AX3; X-ray; 2.98 A; A=1-360.
DR   PDB; 5BUE; X-ray; 2.40 A; A=2-360.
DR   PDB; 5BUI; X-ray; 2.12 A; A=2-360.
DR   PDB; 5BUJ; X-ray; 1.85 A; A=2-360.
DR   PDB; 5BVD; X-ray; 1.90 A; A=2-360.
DR   PDB; 5BVE; X-ray; 2.00 A; A=2-360.
DR   PDB; 5BVF; X-ray; 1.90 A; A=2-360.
DR   PDB; 5K4I; X-ray; 1.76 A; A=9-360.
DR   PDB; 5LCJ; X-ray; 1.78 A; A=1-360.
DR   PDB; 5LCK; X-ray; 1.89 A; A=1-360.
DR   PDB; 5NGU; X-ray; 2.74 A; A=1-360.
DR   PDB; 5NHF; X-ray; 2.14 A; A=1-360.
DR   PDB; 5NHH; X-ray; 1.94 A; A=1-360.
DR   PDB; 5NHJ; X-ray; 2.12 A; A=1-360.
DR   PDB; 5NHL; X-ray; 2.07 A; A=1-360.
DR   PDB; 5NHO; X-ray; 2.24 A; A=1-360.
DR   PDB; 5NHP; X-ray; 1.99 A; A=1-360.
DR   PDB; 5NHV; X-ray; 2.00 A; A=1-360.
DR   PDB; 5V60; X-ray; 2.18 A; A=8-360.
DR   PDB; 5V61; X-ray; 2.20 A; A=8-360.
DR   PDB; 5V62; X-ray; 1.90 A; A=10-360.
DR   PDB; 5WP1; X-ray; 1.40 A; A=4-360.
DR   PDB; 6D5Y; X-ray; 2.86 A; A=13-360.
DR   PDB; 6DMG; X-ray; 2.20 A; A=11-357.
DR   PDB; 6G54; X-ray; 2.05 A; A=1-360.
DR   PDB; 6G8X; X-ray; 1.76 A; A=1-360.
DR   PDB; 6G91; X-ray; 1.80 A; A=1-360.
DR   PDB; 6G92; X-ray; 1.99 A; A=1-360.
DR   PDB; 6G93; X-ray; 1.67 A; A=1-360.
DR   PDB; 6G97; X-ray; 1.90 A; A=1-360.
DR   PDB; 6G9A; X-ray; 1.91 A; A=1-360.
DR   PDB; 6G9D; X-ray; 1.80 A; A=1-360.
DR   PDB; 6G9H; X-ray; 1.73 A; A=1-360.
DR   PDB; 6G9J; X-ray; 1.98 A; A=1-360.
DR   PDB; 6G9K; X-ray; 1.94 A; A=1-360.
DR   PDB; 6G9M; X-ray; 1.86 A; A=1-360.
DR   PDB; 6G9N; X-ray; 1.76 A; A=1-360.
DR   PDB; 6GDM; X-ray; 1.91 A; A=1-360.
DR   PDB; 6GDQ; X-ray; 1.86 A; A=1-360.
DR   PDB; 6GE0; X-ray; 1.82 A; A=1-360.
DR   PDB; 6GJB; X-ray; 1.82 A; A=1-360.
DR   PDB; 6GJD; X-ray; 1.58 A; A=1-360.
DR   PDB; 6NBS; X-ray; 1.90 A; A=9-360.
DR   PDB; 6OPG; X-ray; 2.90 A; A=8-360.
DR   PDB; 6OPH; X-ray; 2.40 A; A=8-360.
DR   PDB; 6OPI; X-ray; 3.00 A; A=8-360.
DR   PDB; 6Q7K; X-ray; 1.84 A; A=1-360.
DR   PDB; 6Q7S; X-ray; 1.73 A; A=1-360.
DR   PDB; 6Q7T; X-ray; 1.60 A; A=1-360.
DR   PDB; 6QA1; X-ray; 1.58 A; A=1-360.
DR   PDB; 6QA3; X-ray; 1.57 A; A=1-360.
DR   PDB; 6QA4; X-ray; 1.60 A; A=1-360.
DR   PDB; 6QAG; X-ray; 2.07 A; A=1-360.
DR   PDB; 6QAH; X-ray; 1.58 A; A=1-360.
DR   PDB; 6QAL; X-ray; 1.57 A; A=1-360.
DR   PDB; 6QAQ; X-ray; 1.58 A; A=1-360.
DR   PDB; 6QAW; X-ray; 1.84 A; A=1-360.
DR   PDB; 6RQ4; X-ray; 1.96 A; A=1-360.
DR   PDB; 6SLG; X-ray; 1.33 A; A=1-360.
DR   PDB; 7AUV; X-ray; 1.76 A; A=1-360.
DR   PDB; 7E73; X-ray; 2.28 A; A=1-360.
DR   PDB; 7E75; X-ray; 2.48 A; A=1-360.
DR   PDB; 7NQQ; X-ray; 1.94 A; A=1-360.
DR   PDB; 7NQW; X-ray; 1.77 A; A=1-360.
DR   PDB; 7NR3; X-ray; 1.90 A; A=1-360.
DR   PDB; 7NR5; X-ray; 1.77 A; A=1-360.
DR   PDB; 7NR8; X-ray; 1.63 A; A=1-360.
DR   PDB; 7NR9; X-ray; 1.91 A; A=1-360.
DR   PDB; 7OPM; X-ray; 2.45 A; A=1-360.
DR   PDB; 7W5O; X-ray; 2.35 A; A/B=1-360.
DR   PDBsum; 1PME; -.
DR   PDBsum; 1TVO; -.
DR   PDBsum; 1WZY; -.
DR   PDBsum; 2OJG; -.
DR   PDBsum; 2OJI; -.
DR   PDBsum; 2OJJ; -.
DR   PDBsum; 2Y9Q; -.
DR   PDBsum; 3D42; -.
DR   PDBsum; 3D44; -.
DR   PDBsum; 3I5Z; -.
DR   PDBsum; 3I60; -.
DR   PDBsum; 3SA0; -.
DR   PDBsum; 3TEI; -.
DR   PDBsum; 3W55; -.
DR   PDBsum; 4FMQ; -.
DR   PDBsum; 4FUX; -.
DR   PDBsum; 4FUY; -.
DR   PDBsum; 4FV0; -.
DR   PDBsum; 4FV1; -.
DR   PDBsum; 4FV2; -.
DR   PDBsum; 4FV3; -.
DR   PDBsum; 4FV4; -.
DR   PDBsum; 4FV5; -.
DR   PDBsum; 4FV6; -.
DR   PDBsum; 4FV7; -.
DR   PDBsum; 4FV8; -.
DR   PDBsum; 4FV9; -.
DR   PDBsum; 4G6N; -.
DR   PDBsum; 4G6O; -.
DR   PDBsum; 4H3P; -.
DR   PDBsum; 4H3Q; -.
DR   PDBsum; 4IZ5; -.
DR   PDBsum; 4IZ7; -.
DR   PDBsum; 4IZA; -.
DR   PDBsum; 4N0S; -.
DR   PDBsum; 4NIF; -.
DR   PDBsum; 4O6E; -.
DR   PDBsum; 4QP1; -.
DR   PDBsum; 4QP2; -.
DR   PDBsum; 4QP3; -.
DR   PDBsum; 4QP4; -.
DR   PDBsum; 4QP6; -.
DR   PDBsum; 4QP7; -.
DR   PDBsum; 4QP8; -.
DR   PDBsum; 4QP9; -.
DR   PDBsum; 4QPA; -.
DR   PDBsum; 4QTA; -.
DR   PDBsum; 4QTE; -.
DR   PDBsum; 4XJ0; -.
DR   PDBsum; 4ZXT; -.
DR   PDBsum; 4ZZM; -.
DR   PDBsum; 4ZZN; -.
DR   PDBsum; 4ZZO; -.
DR   PDBsum; 5AX3; -.
DR   PDBsum; 5BUE; -.
DR   PDBsum; 5BUI; -.
DR   PDBsum; 5BUJ; -.
DR   PDBsum; 5BVD; -.
DR   PDBsum; 5BVE; -.
DR   PDBsum; 5BVF; -.
DR   PDBsum; 5K4I; -.
DR   PDBsum; 5LCJ; -.
DR   PDBsum; 5LCK; -.
DR   PDBsum; 5NGU; -.
DR   PDBsum; 5NHF; -.
DR   PDBsum; 5NHH; -.
DR   PDBsum; 5NHJ; -.
DR   PDBsum; 5NHL; -.
DR   PDBsum; 5NHO; -.
DR   PDBsum; 5NHP; -.
DR   PDBsum; 5NHV; -.
DR   PDBsum; 5V60; -.
DR   PDBsum; 5V61; -.
DR   PDBsum; 5V62; -.
DR   PDBsum; 5WP1; -.
DR   PDBsum; 6D5Y; -.
DR   PDBsum; 6DMG; -.
DR   PDBsum; 6G54; -.
DR   PDBsum; 6G8X; -.
DR   PDBsum; 6G91; -.
DR   PDBsum; 6G92; -.
DR   PDBsum; 6G93; -.
DR   PDBsum; 6G97; -.
DR   PDBsum; 6G9A; -.
DR   PDBsum; 6G9D; -.
DR   PDBsum; 6G9H; -.
DR   PDBsum; 6G9J; -.
DR   PDBsum; 6G9K; -.
DR   PDBsum; 6G9M; -.
DR   PDBsum; 6G9N; -.
DR   PDBsum; 6GDM; -.
DR   PDBsum; 6GDQ; -.
DR   PDBsum; 6GE0; -.
DR   PDBsum; 6GJB; -.
DR   PDBsum; 6GJD; -.
DR   PDBsum; 6NBS; -.
DR   PDBsum; 6OPG; -.
DR   PDBsum; 6OPH; -.
DR   PDBsum; 6OPI; -.
DR   PDBsum; 6Q7K; -.
DR   PDBsum; 6Q7S; -.
DR   PDBsum; 6Q7T; -.
DR   PDBsum; 6QA1; -.
DR   PDBsum; 6QA3; -.
DR   PDBsum; 6QA4; -.
DR   PDBsum; 6QAG; -.
DR   PDBsum; 6QAH; -.
DR   PDBsum; 6QAL; -.
DR   PDBsum; 6QAQ; -.
DR   PDBsum; 6QAW; -.
DR   PDBsum; 6RQ4; -.
DR   PDBsum; 6SLG; -.
DR   PDBsum; 7AUV; -.
DR   PDBsum; 7E73; -.
DR   PDBsum; 7E75; -.
DR   PDBsum; 7NQQ; -.
DR   PDBsum; 7NQW; -.
DR   PDBsum; 7NR3; -.
DR   PDBsum; 7NR5; -.
DR   PDBsum; 7NR8; -.
DR   PDBsum; 7NR9; -.
DR   PDBsum; 7OPM; -.
DR   PDBsum; 7W5O; -.
DR   AlphaFoldDB; P28482; -.
DR   BMRB; P28482; -.
DR   SMR; P28482; -.
DR   BioGRID; 111580; 406.
DR   CORUM; P28482; -.
DR   DIP; DIP-519N; -.
DR   ELM; P28482; -.
DR   IntAct; P28482; 158.
DR   MINT; P28482; -.
DR   STRING; 9606.ENSP00000215832; -.
DR   BindingDB; P28482; -.
DR   ChEMBL; CHEMBL4040; -.
DR   DrugBank; DB07788; (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE.
DR   DrugBank; DB07264; (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE.
DR   DrugBank; DB08521; 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine.
DR   DrugBank; DB07794; 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE.
DR   DrugBank; DB08513; [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB01169; Arsenic trioxide.
DR   DrugBank; DB07905; Hypothemycin.
DR   DrugBank; DB01017; Minocycline.
DR   DrugBank; DB06877; N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE.
DR   DrugBank; DB07010; N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE.
DR   DrugBank; DB02116; Olomoucine.
DR   DrugBank; DB06641; Perifosine.
DR   DrugBank; DB02482; Phosphonothreonine.
DR   DrugBank; DB02733; Purvalanol.
DR   DrugBank; DB04338; SB220025.
DR   DrugBank; DB06195; Seliciclib.
DR   DrugBank; DB11120; Turpentine.
DR   DrugBank; DB13930; Ulixertinib.
DR   DrugCentral; P28482; -.
DR   GuidetoPHARMACOLOGY; 1495; -.
DR   MoonDB; P28482; Predicted.
DR   MoonProt; P28482; -.
DR   iPTMnet; P28482; -.
DR   MetOSite; P28482; -.
DR   PhosphoSitePlus; P28482; -.
DR   SwissPalm; P28482; -.
DR   BioMuta; MAPK1; -.
DR   DMDM; 119554; -.
DR   OGP; P28482; -.
DR   CPTAC; CPTAC-1352; -.
DR   CPTAC; CPTAC-1353; -.
DR   CPTAC; CPTAC-1354; -.
DR   CPTAC; CPTAC-1541; -.
DR   CPTAC; CPTAC-870; -.
DR   CPTAC; CPTAC-871; -.
DR   EPD; P28482; -.
DR   jPOST; P28482; -.
DR   MassIVE; P28482; -.
DR   MaxQB; P28482; -.
DR   PaxDb; P28482; -.
DR   PeptideAtlas; P28482; -.
DR   PRIDE; P28482; -.
DR   ProteomicsDB; 1826; -.
DR   ProteomicsDB; 54488; -. [P28482-1]
DR   Antibodypedia; 3785; 1904 antibodies from 54 providers.
DR   CPTC; P28482; 4 antibodies.
DR   DNASU; 5594; -.
DR   Ensembl; ENST00000215832.11; ENSP00000215832.7; ENSG00000100030.15. [P28482-1]
DR   Ensembl; ENST00000398822.7; ENSP00000381803.3; ENSG00000100030.15. [P28482-1]
DR   Ensembl; ENST00000544786.1; ENSP00000440842.1; ENSG00000100030.15. [P28482-2]
DR   GeneID; 5594; -.
DR   KEGG; hsa:5594; -.
DR   MANE-Select; ENST00000215832.11; ENSP00000215832.7; NM_002745.5; NP_002736.3.
DR   UCSC; uc010gtk.2; human. [P28482-1]
DR   CTD; 5594; -.
DR   DisGeNET; 5594; -.
DR   GeneCards; MAPK1; -.
DR   HGNC; HGNC:6871; MAPK1.
DR   HPA; ENSG00000100030; Low tissue specificity.
DR   MalaCards; MAPK1; -.
DR   MIM; 176948; gene.
DR   MIM; 619087; phenotype.
DR   neXtProt; NX_P28482; -.
DR   OpenTargets; ENSG00000100030; -.
DR   Orphanet; 261330; Distal 22q11.2 microdeletion syndrome.
DR   PharmGKB; PA30616; -.
DR   VEuPathDB; HostDB:ENSG00000100030; -.
DR   eggNOG; KOG0660; Eukaryota.
DR   GeneTree; ENSGT00940000156771; -.
DR   HOGENOM; CLU_000288_181_1_1; -.
DR   InParanoid; P28482; -.
DR   OMA; SFFDFDY; -.
DR   PhylomeDB; P28482; -.
DR   TreeFam; TF105097; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   PathwayCommons; P28482; -.
DR   Reactome; R-HSA-111995; phospho-PLA2 pathway.
DR   Reactome; R-HSA-112409; RAF-independent MAPK1/3 activation.
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-HSA-1181150; Signaling by NODAL.
DR   Reactome; R-HSA-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-HSA-1502540; Signaling by Activin.
DR   Reactome; R-HSA-162658; Golgi Cisternae Pericentriolar Stack Reorganization.
DR   Reactome; R-HSA-170968; Frs2-mediated activation.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-202670; ERKs are inactivated.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   Reactome; R-HSA-444257; RSK activation.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors.
DR   Reactome; R-HSA-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   Reactome; R-HSA-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway.
DR   Reactome; R-HSA-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-74749; Signal attenuation.
DR   Reactome; R-HSA-879415; Advanced glycosylation endproduct receptor signaling.
DR   Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK.
DR   Reactome; R-HSA-8939211; ESR-mediated signaling.
DR   Reactome; R-HSA-8940973; RUNX2 regulates osteoblast differentiation.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-HSA-9627069; Regulation of the apoptosome activity.
DR   Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ.
DR   Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling.
DR   Reactome; R-HSA-9635465; Suppression of apoptosis.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9652169; Signaling by MAP2K mutants.
DR   Reactome; R-HSA-9652817; Signaling by MAPK mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-9725371; Nuclear events stimulated by ALK signaling in cancer.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   SABIO-RK; P28482; -.
DR   SignaLink; P28482; -.
DR   SIGNOR; P28482; -.
DR   BioGRID-ORCS; 5594; 147 hits in 1126 CRISPR screens.
DR   ChiTaRS; MAPK1; human.
DR   EvolutionaryTrace; P28482; -.
DR   GeneWiki; MAPK1; -.
DR   GenomeRNAi; 5594; -.
DR   Pharos; P28482; Tchem.
DR   PRO; PR:P28482; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; P28482; protein.
DR   Bgee; ENSG00000100030; Expressed in middle temporal gyrus and 209 other tissues.
DR   ExpressionAtlas; P28482; baseline and differential.
DR   Genevisible; P28482; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0005901; C:caveola; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:UniProtKB.
DR   GO; GO:0005769; C:early endosome; TAS:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; TAS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:UniProtKB.
DR   GO; GO:0005770; C:late endosome; TAS:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; TAS:UniProtKB.
DR   GO; GO:0072686; C:mitotic spindle; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0031143; C:pseudopodium; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004707; F:MAP kinase activity; IBA:GO_Central.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IEA:Ensembl.
DR   GO; GO:0019902; F:phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; ISS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0061308; P:cardiac neural crest cell development involved in heart development; IEA:Ensembl.
DR   GO; GO:0072584; P:caveolin-mediated endocytosis; TAS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IDA:CAFA.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IMP:CAFA.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IEA:Ensembl.
DR   GO; GO:1903351; P:cellular response to dopamine; IMP:CAFA.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IMP:CAFA.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0006935; P:chemotaxis; TAS:ProtInc.
DR   GO; GO:0019858; P:cytosine metabolic process; IEA:Ensembl.
DR   GO; GO:0038127; P:ERBB signaling pathway; IDA:UniProtKB.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0060324; P:face development; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0060716; P:labyrinthine layer blood vessel development; IEA:Ensembl.
DR   GO; GO:0007611; P:learning or memory; NAS:ARUK-UCL.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0060425; P:lung morphogenesis; IEA:Ensembl.
DR   GO; GO:0033598; P:mammary gland epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IEA:Ensembl.
DR   GO; GO:0042473; P:outer ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:CAFA.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; IGI:ARUK-UCL.
DR   GO; GO:0120041; P:positive regulation of macrophage proliferation; IGI:ARUK-UCL.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:1904355; P:positive regulation of telomere capping; IMP:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030641; P:regulation of cellular pH; IEA:Ensembl.
DR   GO; GO:0051493; P:regulation of cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:2000641; P:regulation of early endosome to late endosome transport; TAS:UniProtKB.
DR   GO; GO:0090170; P:regulation of Golgi inheritance; TAS:UniProtKB.
DR   GO; GO:0030278; P:regulation of ossification; IEA:Ensembl.
DR   GO; GO:0031647; P:regulation of protein stability; ISS:UniProtKB.
DR   GO; GO:0032872; P:regulation of stress-activated MAPK cascade; TAS:UniProtKB.
DR   GO; GO:0070849; P:response to epidermal growth factor; IDA:UniProtKB.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0035094; P:response to nicotine; ISS:ARUK-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:CAFA.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0030878; P:thyroid gland development; IEA:Ensembl.
DR   GO; GO:0060440; P:trachea formation; IEA:Ensembl.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008349; MAPK_ERK1/2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01770; ERK1ERK2MAPK.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding;
KW   Cell cycle; Cell junction; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Disease variant; DNA-binding;
KW   Host-virus interaction; Kinase; Membrane; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repressor;
KW   Serine/threonine-protein kinase; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12665801,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   CHAIN           2..360
FT                   /note="Mitogen-activated protein kinase 1"
FT                   /id="PRO_0000186247"
FT   DOMAIN          25..313
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DNA_BIND        259..277
FT   MOTIF           185..187
FT                   /note="TXY"
FT                   /evidence="ECO:0000269|PubMed:18760948"
FT   MOTIF           318..322
FT                   /note="Cytoplasmic retention motif"
FT                   /evidence="ECO:0000269|PubMed:18760948"
FT   MOTIF           327..333
FT                   /note="Nuclear translocation motif"
FT                   /evidence="ECO:0000269|PubMed:18760948"
FT   ACT_SITE        149
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         31..39
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         54
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|PubMed:12665801,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         29
FT                   /note="Phosphoserine; by SGK1"
FT                   /evidence="ECO:0000269|PubMed:19447520"
FT   MOD_RES         185
FT                   /note="Phosphothreonine; by MAP2K1 and MAP2K2"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         187
FT                   /note="Phosphotyrosine; by MAP2K1 and MAP2K2"
FT                   /evidence="ECO:0000269|PubMed:19053285,
FT                   ECO:0000269|PubMed:19494114, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         190
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:19060905"
FT   MOD_RES         246
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18760948"
FT   MOD_RES         248
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18760948"
FT   MOD_RES         284
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   VAR_SEQ         242..285
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_047815"
FT   VARIANT         74
FT                   /note="I -> N (in NS13; results in increased MAPK
FT                   signaling; reduced interaction wth DUSP6; no effect on
FT                   interaction with MAP2K1)"
FT                   /evidence="ECO:0000269|PubMed:32721402"
FT                   /id="VAR_085093"
FT   VARIANT         80
FT                   /note="H -> Y (in NS13; results in increased MAPK
FT                   signaling; reduced interaction wth DUSP6; no effect on
FT                   interaction with MAP2K1)"
FT                   /evidence="ECO:0000269|PubMed:32721402"
FT                   /id="VAR_085094"
FT   VARIANT         174
FT                   /note="A -> V (in NS13; results in increased MAPK
FT                   signaling; increased translocation to the nucleus; reduced
FT                   interaction wth DUSP6; no effect on interaction with
FT                   MAP2K1)"
FT                   /evidence="ECO:0000269|PubMed:32721402"
FT                   /id="VAR_085095"
FT   VARIANT         318
FT                   /note="D -> G (in NS13; results in increased MAPK
FT                   signaling; increased translocation to the nucleus; reduced
FT                   interaction wth DUSP6; no effect on interaction with
FT                   MAP2K1)"
FT                   /evidence="ECO:0000269|PubMed:32721402"
FT                   /id="VAR_085096"
FT   VARIANT         318
FT                   /note="D -> N (in NS13; results in increased MAPK
FT                   signaling; increased translocation to the nucleus; reduced
FT                   interaction wth DUSP6; no effect on interaction with
FT                   MAP2K1)"
FT                   /evidence="ECO:0000269|PubMed:32721402"
FT                   /id="VAR_085097"
FT   VARIANT         322
FT                   /note="E -> Q (in NS13)"
FT                   /evidence="ECO:0000269|PubMed:32721402"
FT                   /id="VAR_085098"
FT   VARIANT         323
FT                   /note="P -> R (in NS13; results in increased MAPK
FT                   signaling; increased translocation to the nucleus; reduced
FT                   interaction wth DUSP6; no effect on interaction with
FT                   MAP2K1)"
FT                   /evidence="ECO:0000269|PubMed:32721402"
FT                   /id="VAR_085099"
FT   MUTAGEN         54
FT                   /note="K->R: Does not inhibit interaction with MAP2K1."
FT                   /evidence="ECO:0000269|PubMed:18794356"
FT   MUTAGEN         176..179
FT                   /note="Missing: Inhibits homodimerization and interaction
FT                   with TPR."
FT                   /evidence="ECO:0000269|PubMed:18794356"
FT   MUTAGEN         185
FT                   /note="T->A: Inhibits interaction with TPR; when associated
FT                   with A-187."
FT                   /evidence="ECO:0000269|PubMed:18794356"
FT   MUTAGEN         187
FT                   /note="Y->A: Inhibits interaction with TPR; when associated
FT                   with A-185."
FT                   /evidence="ECO:0000269|PubMed:18794356"
FT   MUTAGEN         234
FT                   /note="L->A: Inhibits interaction with TPR."
FT                   /evidence="ECO:0000269|PubMed:18794356"
FT   MUTAGEN         318
FT                   /note="D->A: Loss of dephosphorylation by PTPRJ."
FT                   /evidence="ECO:0000269|PubMed:18794356,
FT                   ECO:0000269|PubMed:19494114"
FT   MUTAGEN         318
FT                   /note="D->N: Inhibits interaction with MAP2K1 but not with
FT                   TPR; when associated with N-321."
FT                   /evidence="ECO:0000269|PubMed:18794356,
FT                   ECO:0000269|PubMed:19494114"
FT   MUTAGEN         321
FT                   /note="D->N: Inhibits interaction with MAP2K1 but not with
FT                   TPR; when associated with N-318."
FT                   /evidence="ECO:0000269|PubMed:18794356"
FT   CONFLICT        91
FT                   /note="R -> Q (in Ref. 2; CAA77752)"
FT                   /evidence="ECO:0000305"
FT   HELIX           2..7
FT                   /evidence="ECO:0007829|PDB:7OPM"
FT   STRAND          12..14
FT                   /evidence="ECO:0007829|PDB:4QTA"
FT   STRAND          17..19
FT                   /evidence="ECO:0007829|PDB:4QTA"
FT   TURN            22..24
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   STRAND          25..34
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   STRAND          37..44
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   TURN            45..48
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   STRAND          49..56
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   STRAND          59..61
FT                   /evidence="ECO:0007829|PDB:6G92"
FT   HELIX           62..77
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   STRAND          81..83
FT                   /evidence="ECO:0007829|PDB:5AX3"
FT   STRAND          88..90
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   TURN            95..97
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   STRAND          101..106
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   STRAND          109..111
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           112..118
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           123..142
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           152..154
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   STRAND          155..157
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   TURN            159..161
FT                   /evidence="ECO:0007829|PDB:4IZ5"
FT   STRAND          163..165
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           168..170
FT                   /evidence="ECO:0007829|PDB:3I5Z"
FT   HELIX           176..178
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   TURN            181..185
FT                   /evidence="ECO:0007829|PDB:2Y9Q"
FT   HELIX           191..193
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           196..200
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   STRAND          201..203
FT                   /evidence="ECO:0007829|PDB:5K4I"
FT   HELIX           208..223
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           235..244
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           249..253
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           258..265
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           275..278
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   STRAND          280..282
FT                   /evidence="ECO:0007829|PDB:5NHO"
FT   HELIX           284..293
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   TURN            298..300
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           304..308
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           311..313
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   TURN            314..316
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           319..321
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           331..334
FT                   /evidence="ECO:0007829|PDB:5V62"
FT   HELIX           335..337
FT                   /evidence="ECO:0007829|PDB:5K4I"
FT   HELIX           340..351
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   HELIX           352..354
FT                   /evidence="ECO:0007829|PDB:4ZZN"
FT   TURN            356..358
FT                   /evidence="ECO:0007829|PDB:1PME"
SQ   SEQUENCE   360 AA;  41390 MW;  E85D0B2A5D2D724E CRC64;
     MAAAAAAGAG PEMVRGQVFD VGPRYTNLSY IGEGAYGMVC SAYDNVNKVR VAIKKISPFE
     HQTYCQRTLR EIKILLRFRH ENIIGINDII RAPTIEQMKD VYIVQDLMET DLYKLLKTQH
     LSNDHICYFL YQILRGLKYI HSANVLHRDL KPSNLLLNTT CDLKICDFGL ARVADPDHDH
     TGFLTEYVAT RWYRAPEIML NSKGYTKSID IWSVGCILAE MLSNRPIFPG KHYLDQLNHI
     LGILGSPSQE DLNCIINLKA RNYLLSLPHK NKVPWNRLFP NADSKALDLL DKMLTFNPHK
     RIEVEQALAH PYLEQYYDPS DEPIAEAPFK FDMELDDLPK EKLKELIFEE TARFQPGYRS
//
